123 citations
,
September 1987 in “JAMA” This study observed that patients receiving IL-2 immunotherapy developed a skin eruption characterized by burning and pruritus, which resolved shortly after stopping the infusion, suggesting that IL-2 mediated these effects.
34 citations
,
January 2022 in “Frontiers in Immunology” This study found that IL-25-mediated-IL-17RB signaling improved diabetic wound healing by enhancing angiogenesis, collagen deposition, and endothelial cell function, suggesting a potential therapeutic strategy for poorly healing diabetic wounds.
25 citations
,
July 1994 in “Archives of Dermatology” This study describes a patient with metastatic renal cell carcinoma who experienced a recurrence of pemphigus vulgaris after receiving interleukin 2 immunotherapy, suggesting a possible link between the treatment and autoimmune disease recurrence.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This study found that alopecia areata patients had higher baseline interleukin levels, which significantly decreased with tofacitinib treatment, though this change did not correspond to disease severity improvement.
December 2024 in “Kufa Medical journal” The study reported that patients with alopecia areata had significantly higher serum levels of IL-17A and IL-2 compared to healthy controls, suggesting these interleukins may play an important role in the disease, though they did not correlate with its severity or duration.